The mantle cell lymphoma condition center is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma. Read more at OncLive.
May 2nd 2024
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
April 18th 2024
William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.
April 17th 2024
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.
April 16th 2024
William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.
April 5th 2024
Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.
March 29th 2024
Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.
CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.
March 28th 2024
Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.
Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.
March 27th 2024
Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.
March 22nd 2024
A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.
March 21st 2024
TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.
March 11th 2024
The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies
March 7th 2024
Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.
March 5th 2024
Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.
February 28th 2024
Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.
February 26th 2024
In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.
February 22nd 2024
Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.
Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features.